Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Research

Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by multi-omic data analysis

Authors: Chengxing Wang, Yaoming He, Yu He, Weijun Liang, Chaorong Zhou, Meimei Wu, Zijie Meng, Wanglin Li, Jie Cao

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Colorectal cancer (CRC) is one of the most common malignancies in the world. This study proposes to reveal prognostic biomarkers for the prognosis and treatment of CRC patients.

Methods

Differential analysis of OSBPL3 was performed in pan-cancer, and the correlation between clinical stage and OSBPL3 was analyzed. Multiple omics analysis was used to compare the relationship between survival of patients and copy number variation, single nucleotide variant, and methylation status. Survival differences between high and low OSBPL3 expression groups were analyzed. Differentially expressed genes (DEGs) between high and low OSBPL3 expression groups were obtained, and functional enrichment analysis was implemented. Correlations between immune cells and OSBPL3 was analyzed. Drug sensitivity between the two OSBPL3 expression groups was compared. Moreover, the expression of OSBPL3 was verified by immunohistochemistry and real-time quantitative PCR.

Results

OSBPL3 was differentially expressed in 13 tumors and had some correlations with T and N stages. OSBPL3 expression was regulated by methylation and higher OSBPL3 expression was associated with poorer prognosis in CRC. 128 DEGs were obtained and they were mainly involved in signaling receptor activator activity, aspartate and glutamate metabolism. T cell gamma delta and T cell follicular helper were significantly different in the high and low OSBPL3 expression groups. Moreover, OSBPL3 showed negative correlations with multiple drugs. OSBPL3 was significantly upregulated in CRC samples compared to normal samples.

Conclusions

A comprehensive analysis demonstrated that OSBPL3 had potential prognostic value, and guiding significance for CRC chemotherapeutic.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
3.
go back to reference Watts K, Wills C, Madi A, et al. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. Int J Cancer. 2021;149(9):1713–22.PubMed Watts K, Wills C, Madi A, et al. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. Int J Cancer. 2021;149(9):1713–22.PubMed
4.
go back to reference Lehto M, Laitinen S, Chinetti G, et al. The OSBP-related protein family in humans. J Lipid Res. 2001;42(8):1203–13.PubMed Lehto M, Laitinen S, Chinetti G, et al. The OSBP-related protein family in humans. J Lipid Res. 2001;42(8):1203–13.PubMed
5.
go back to reference Collier FM, Gregorio-King CC, Apostolopoulos J, Walder K, Kirkland MA. ORP3 splice variants and their expression in human tissues and hematopoietic cells. DNA Cell Biol. 2003;22(1):1–9.PubMed Collier FM, Gregorio-King CC, Apostolopoulos J, Walder K, Kirkland MA. ORP3 splice variants and their expression in human tissues and hematopoietic cells. DNA Cell Biol. 2003;22(1):1–9.PubMed
6.
go back to reference Lehto M, Mäyränpää MI, Pellinen T, et al. The R-Ras interaction partner ORP3 regulates cell adhesion. J Cell Sci. 2008;121(Pt 5):695–705.PubMed Lehto M, Mäyränpää MI, Pellinen T, et al. The R-Ras interaction partner ORP3 regulates cell adhesion. J Cell Sci. 2008;121(Pt 5):695–705.PubMed
7.
go back to reference Kentala H, Weber-Boyvat M, Olkkonen VM. OSBP-Related Protein Family: Mediators of Lipid Transport and Signaling at Membrane Contact Sites. Int Rev Cell Mol Biol. 2016;321:299–340.PubMed Kentala H, Weber-Boyvat M, Olkkonen VM. OSBP-Related Protein Family: Mediators of Lipid Transport and Signaling at Membrane Contact Sites. Int Rev Cell Mol Biol. 2016;321:299–340.PubMed
8.
go back to reference Olkkonen VM. OSBP-Related Protein Family in Lipid Transport Over Membrane Contact Sites. Lipid insights. 2015;8(Suppl 1):1–9.PubMedPubMedCentral Olkkonen VM. OSBP-Related Protein Family in Lipid Transport Over Membrane Contact Sites. Lipid insights. 2015;8(Suppl 1):1–9.PubMedPubMedCentral
9.
go back to reference Zhang Y, Luo J, Liu Z, et al. Identification of hub genes in colorectal cancer based on weighted gene co-expression network analysis and clinical data from The Cancer Genome Atlas. Biosci Rep. 2021;41(7):BSR20211280.PubMedPubMedCentral Zhang Y, Luo J, Liu Z, et al. Identification of hub genes in colorectal cancer based on weighted gene co-expression network analysis and clinical data from The Cancer Genome Atlas. Biosci Rep. 2021;41(7):BSR20211280.PubMedPubMedCentral
10.
go back to reference Li H, Wang X, Fang Y, et al. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(32):52571–83.PubMedPubMedCentral Li H, Wang X, Fang Y, et al. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(32):52571–83.PubMedPubMedCentral
11.
go back to reference Chhatriya B, Mukherjee M, Ray S, et al. Transcriptome analysis identifies putative multi-gene signature distinguishing benign and malignant pancreatic head mass. J Transl Med. 2020;18(1):420.PubMedPubMedCentral Chhatriya B, Mukherjee M, Ray S, et al. Transcriptome analysis identifies putative multi-gene signature distinguishing benign and malignant pancreatic head mass. J Transl Med. 2020;18(1):420.PubMedPubMedCentral
12.
go back to reference Hu Q, Masuda T, Koike K, et al. Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. Sci Rep. 2021;11(1):19178.PubMedPubMedCentral Hu Q, Masuda T, Koike K, et al. Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. Sci Rep. 2021;11(1):19178.PubMedPubMedCentral
13.
go back to reference Lefebvre C, Bachelot T, Filleron T, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.PubMedPubMedCentral Lefebvre C, Bachelot T, Filleron T, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.PubMedPubMedCentral
14.
go back to reference Chen J, Song Y, Li M, et al. Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer. BMC Cancer. 2021;21(1):255.PubMedPubMedCentral Chen J, Song Y, Li M, et al. Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer. BMC Cancer. 2021;21(1):255.PubMedPubMedCentral
15.
go back to reference Tian Y, Morris TJ, Webster AP, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics (Oxford, England). 2017;33(24):3982–4.PubMed Tian Y, Morris TJ, Webster AP, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics (Oxford, England). 2017;33(24):3982–4.PubMed
16.
go back to reference Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentral Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentral
17.
go back to reference Ito K, Murphy D. Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e79.PubMedPubMedCentral Ito K, Murphy D. Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e79.PubMedPubMedCentral
18.
go back to reference Cheng Q, Wang L. LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212–3p and hsa-miR-122–5p. Cell Cycle (Georgetown, Tex). 2020;19(3):290–9.PubMed Cheng Q, Wang L. LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212–3p and hsa-miR-122–5p. Cell Cycle (Georgetown, Tex). 2020;19(3):290–9.PubMed
20.
21.
go back to reference Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592.PubMed Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592.PubMed
22.
go back to reference Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol (Clifton, NJ). 2018;1711:243–59. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol (Clifton, NJ). 2018;1711:243–59.
23.
go back to reference Wang C, Wang B, Liang W, et al. Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10. BMC Cancer. 2022;22(1):922.PubMedPubMedCentral Wang C, Wang B, Liang W, et al. Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10. BMC Cancer. 2022;22(1):922.PubMedPubMedCentral
24.
go back to reference Wang C, Li X, Ren L, et al. Gankyrin as potential biomarker for colorectal cancer with occult liver metastases. Front Oncol. 2021;11:656852.PubMedPubMedCentral Wang C, Li X, Ren L, et al. Gankyrin as potential biomarker for colorectal cancer with occult liver metastases. Front Oncol. 2021;11:656852.PubMedPubMedCentral
25.
go back to reference Stefani C, Miricescu D, Stanescu S II, et al. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now? Int J Mol Sci. 2021;22(19):10260.PubMedPubMedCentral Stefani C, Miricescu D, Stanescu S II, et al. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now? Int J Mol Sci. 2021;22(19):10260.PubMedPubMedCentral
26.
go back to reference Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009.PubMed Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009.PubMed
27.
go back to reference Chou CW, Hsieh YH, Ku SC, et al. Potential prognostic biomarkers of OSBPL family genes in patients with pancreatic ductal adenocarcinoma. Biomedicines. 2021;9(11):1601.PubMedPubMedCentral Chou CW, Hsieh YH, Ku SC, et al. Potential prognostic biomarkers of OSBPL family genes in patients with pancreatic ductal adenocarcinoma. Biomedicines. 2021;9(11):1601.PubMedPubMedCentral
28.
go back to reference Holý P, Hlaváč V, Ostašov P, et al. Germline and somatic genetic variability of oxysterol-related genes in breast cancer patients with early disease of the luminal subtype. Biochimie. 2022;199:158–69.PubMed Holý P, Hlaváč V, Ostašov P, et al. Germline and somatic genetic variability of oxysterol-related genes in breast cancer patients with early disease of the luminal subtype. Biochimie. 2022;199:158–69.PubMed
29.
go back to reference Hao N, Zhou Y, Li Y, et al. Clinical Value and Potential Mechanisms of Oxysterol-Binding Protein Like 3 (OSBPL3) in Human Tumors. Front Mol Biosci. 2021;8:739978.PubMedPubMedCentral Hao N, Zhou Y, Li Y, et al. Clinical Value and Potential Mechanisms of Oxysterol-Binding Protein Like 3 (OSBPL3) in Human Tumors. Front Mol Biosci. 2021;8:739978.PubMedPubMedCentral
30.
go back to reference Xu P, Richter J, Blatz A, et al. Downregulation of ORP3 Correlates with Reduced Survival of Colon Cancer Patients with Advanced Nodal Metastasis and of Female Patients with Grade 3 Colon Cancer. Int J Mol Sci. 2020;21(16):5894.PubMedPubMedCentral Xu P, Richter J, Blatz A, et al. Downregulation of ORP3 Correlates with Reduced Survival of Colon Cancer Patients with Advanced Nodal Metastasis and of Female Patients with Grade 3 Colon Cancer. Int J Mol Sci. 2020;21(16):5894.PubMedPubMedCentral
31.
go back to reference Zhang M, Meng L, Zhang Z, et al. The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis. BMC Med Genomics. 2022;15(1):259.PubMedPubMedCentral Zhang M, Meng L, Zhang Z, et al. The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis. BMC Med Genomics. 2022;15(1):259.PubMedPubMedCentral
32.
go back to reference Cusenza VY, Bisagni A, Rinaldini M, Cattani C, Frazzi R. Copy number variation and rearrangements assessment in cancer: comparison of droplet digital PCR with the current approaches. Int J Mol Sci. 2021;22(9):4732.PubMedPubMedCentral Cusenza VY, Bisagni A, Rinaldini M, Cattani C, Frazzi R. Copy number variation and rearrangements assessment in cancer: comparison of droplet digital PCR with the current approaches. Int J Mol Sci. 2021;22(9):4732.PubMedPubMedCentral
33.
go back to reference Panyutin IG, Panyutin IV, Powell-Castilla I, Felix L, Neumann RD. Single nucleotide variations in cultured cancer cells: effect of mismatch repair. Mutat Res. 2017;803–805:22–5.PubMedPubMedCentral Panyutin IG, Panyutin IV, Powell-Castilla I, Felix L, Neumann RD. Single nucleotide variations in cultured cancer cells: effect of mismatch repair. Mutat Res. 2017;803–805:22–5.PubMedPubMedCentral
34.
go back to reference Klutstein M, Nejman D, Greenfield R, Cedar H. DNA Methylation in Cancer and Aging. Can Res. 2016;76(12):3446–50. Klutstein M, Nejman D, Greenfield R, Cedar H. DNA Methylation in Cancer and Aging. Can Res. 2016;76(12):3446–50.
35.
go back to reference Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS, Zou C. RNA methylation and cancer treatment. Pharmacol Res. 2021;174:105937.PubMed Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS, Zou C. RNA methylation and cancer treatment. Pharmacol Res. 2021;174:105937.PubMed
36.
go back to reference Gutierrez A, Demond H, Brebi P, Ili CG. Novel methylation biomarkers for colorectal cancer prognosis. Biomolecules. 2021;11(11):1722.PubMedPubMedCentral Gutierrez A, Demond H, Brebi P, Ili CG. Novel methylation biomarkers for colorectal cancer prognosis. Biomolecules. 2021;11(11):1722.PubMedPubMedCentral
37.
go back to reference Bastid J, Dejou C, Docquier A, Bonnefoy N. The emerging role of the IL-17B/IL-17RB pathway in cancer. Front Immunol. 2020;11:718.PubMedPubMedCentral Bastid J, Dejou C, Docquier A, Bonnefoy N. The emerging role of the IL-17B/IL-17RB pathway in cancer. Front Immunol. 2020;11:718.PubMedPubMedCentral
38.
go back to reference Zheng X, Wei J, Li W, et al. PRDX2 removal inhibits the cell cycle and autophagy in colorectal cancer cells. Aging (Albany NY). 2020;12(16):16390–409.PubMed Zheng X, Wei J, Li W, et al. PRDX2 removal inhibits the cell cycle and autophagy in colorectal cancer cells. Aging (Albany NY). 2020;12(16):16390–409.PubMed
39.
go back to reference Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMed Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMed
40.
go back to reference Ma R, Yuan D, Guo Y, Yan R, Li K. Immune effects of γδ T cells in colorectal cancer: a review. Front Immunol. 2020;11:1600.PubMedPubMedCentral Ma R, Yuan D, Guo Y, Yan R, Li K. Immune effects of γδ T cells in colorectal cancer: a review. Front Immunol. 2020;11:1600.PubMedPubMedCentral
41.
go back to reference Hetta HF, Elkady A, Yahia R, et al. T follicular helper and T follicular regulatory cells in colorectal cancer: a complex interplay. J Immunol Methods. 2020;480:112753.PubMed Hetta HF, Elkady A, Yahia R, et al. T follicular helper and T follicular regulatory cells in colorectal cancer: a complex interplay. J Immunol Methods. 2020;480:112753.PubMed
42.
go back to reference Wang Z, Wang Z, Diao Y, Qian X, Zhu N, Dong W. Circulating follicular helper T cells in Crohn’s disease (CD) and CD-associated colorectal cancer. Tumour Biol. 2014;35(9):9355–9.PubMed Wang Z, Wang Z, Diao Y, Qian X, Zhu N, Dong W. Circulating follicular helper T cells in Crohn’s disease (CD) and CD-associated colorectal cancer. Tumour Biol. 2014;35(9):9355–9.PubMed
43.
go back to reference Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.PubMed Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.PubMed
44.
go back to reference Sipok A, Sardi A, Nieroda C, King MC, Sittig M, Gushchin V. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin-C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1920276.PubMedPubMedCentral Sipok A, Sardi A, Nieroda C, King MC, Sittig M, Gushchin V. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin-C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1920276.PubMedPubMedCentral
45.
go back to reference Chen Y, Bian L, Zhang Y. MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. J Pharm Pharmacol. 2018;70(7):937–51.PubMed Chen Y, Bian L, Zhang Y. MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. J Pharm Pharmacol. 2018;70(7):937–51.PubMed
46.
go back to reference Guo J, Yu Z, Das M, Huang L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano. 2020;14(4):5075–89.PubMed Guo J, Yu Z, Das M, Huang L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano. 2020;14(4):5075–89.PubMed
Metadata
Title
Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by multi-omic data analysis
Authors
Chengxing Wang
Yaoming He
Yu He
Weijun Liang
Chaorong Zhou
Meimei Wu
Zijie Meng
Wanglin Li
Jie Cao
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02824-1

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.